Zipnosis provides a white-labeled, comprehensive virtual care platform that supports multiple modes of patient–clinician interaction and can be fully integrated with a healthcare system’s infrastructure. The platform delivers virtual care for more than 90 conditions and is expanding into chronic conditions such as high blood pressure and high cholesterol. Clinical workflows include an adaptive patient interview that is reviewed by a clinician (typically within an hour) who triages or provides treatment rapidly. As of the article, Zipnosis worked with 20 healthcare organizations across 11 states and employed 30 people, with plans to grow headcount in 2016. Management has an aggressive expansion plan to secure health-system partners in every state and intends to invest significantly in sales and marketing rather than relying solely on client referrals. The company is led by co-founder and CEO Jon Pearce. Zipnosis provides a software-as-a-service telehealth platform that connects patients with local clinicians and is white-labeled for partner health systems. The platform offers prompt care for common conditions (sinus infections, UTIs, pink eye, colds/flu) and charges a flat $25–$35 service fee payable by credit card or health savings card. Zipnosis says its service attracts new patients for health systems and can boost revenues without adding clinical headcount. The company cites industry research forecasting rapid telehealth growth (about 75 million virtual visits and strong revenue expansion) to justify market opportunity. Management expects Arthur Ventures’ investment to help accelerate the company’s exponential, organic growth over the next two years. The product roadmap emphasizes reducing administrative burdens on providers through AI automation as telehealth adoption advances.

Total raised

$19M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2016